What 22 Analyst Ratings Have To Say About Edwards Lifesciences
What 22 Analyst Ratings Have To Say About Edwards Lifesciences
关于爱德华生命科学的22个分析师评级,以下是他们的观点。
Across the recent three months, 22 analysts have shared their insights on Edwards Lifesciences (NYSE:EW), expressing a variety of opinions spanning from bullish to bearish.
在最近的三个月中,22位分析师分享了他们对纽交所(NYSE:EW)的见解,表达了从看好到看淡的各种观点。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
以下表格概括了他们最近的评级,展示了过去30天内的情绪演变并与之前的几个月进行了比较。
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $87.23, along with a high estimate of $110.00 and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.29%.
提供更深入的见解,分析师已经建立了12个月的价格目标,显示出平均目标为87.23美元,高估值为110.00美元,低估值为70.00美元。情绪负面转变显而易见,由于分析师已将平均价目标下调了11.29%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级:详细剖析
An in-depth...
对纽交...
登录免费看全文
登录/注册